From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

OptiBiotix Health – further positive Slimbiome study results, Strong Buy

By Tom Winnifrith & Steve Moore | Monday 24 June 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


OptiBiotix Health (OPTI) has issued a “Slimbiome study results”-titled announcement including that latest results from human studies carried out at Roehampton University “continue to prove the efficacy of Slimbiome to reduce hunger and food cravings which changes the amount and type of food people eat leading to sustainable weight management”. Following a chat with OptiBiotix Chief Executive Stephen O’Hara, the following is why such studies are potentially highly significant.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Thursday »

CCT

Character Group – a Buy?

 

ING

Ingenta – now a Buy again?

 

Clown

Which PR genius wrote this?

 

HAT

H&T Group – now again a Buy

Time left: 00:17:52